Caleb Roberts1,2, Claire L. Mitchell3, James P. O'Connor, 23, Yvonne Watson1,2, Sue Cheung1,2, Alison Backen4, Caroline Dive4, Alan Jackson1,2, Gordon C. Jayson3, Geoff J. Parker1,2
1Imaging Science and Biomedical Engineering, School of Cancer and Imaging Sciences, The University of Manchester, Manchester, United Kingdom; 2The University of Manchester Biomedical Imaging Institute, The University of Manchester, Manchester, United Kingdom; 3Cancer Research UK Dept Medical Oncology, Christie Hospital and University of Manchester, Manchester, United Kingdom; 4Clinical and Experimental Pharmacology Group, Paterson Institute for Cancer Research, Manchester, United Kingdom
The integration of imaging strategies such as dynamic contrast-enhanced MRI (DCE-MRI) in early phase drug development can help elucidate the underlying tumor physiology and assess drug efficacy. This study focuses on the relationships between serological expression of soluble VEGF receptors and DCE-MRI tracer kinetic parameters in a group of ovarian tumors. We observe striking relationships between the serological markers, Ktrans and vp that indicate that DCE-MRI is sensitive to specific aspects of the angiogenic process in these tumors.